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ABSTRACT
The aim of the present study was to evaluate the anti-
allergic effect of apple condensed tannins (ACT) in
patients with atopic dermatitis (AD) as a pilot study.
An ACT supplement given to the patients at oral doses
of 10 mg/kg per day for 8 weeks reduced the inflam-
mation, lichenification, cracking, itching, sleep dis-
turbance and peripheral blood eosinophil counts.
Itching and sleep disturbance scores after ACT supple-
ment even for 2 weeks were significantly decreased
compared with the control group. The results suggest
that ACT has an anti-allergic effect and that its use
improved the symptoms of AD.
Key words: anti-allergic effect, apple polyphenol, atopic
dermatitis.
INTRODUCTION
Apples contain several phenolic substances: chlorogenic
acid, catechin, epicatechin, phlorizin, rutin, flavonoid
and condensed tannins.1–7 Some of these substances
have physiologic and pharmacologic activities. Osada et
al. have demonstrated that apple condensed tannins
(ACT), which are 10-fold higher in unripe apples than in
ripe ones, scavenge active oxygen species.8 Several
authors have reported that oligometric catechins show
antioxidant activities.9,10 Recently, Kanda et al. have
described that ACT has an inhibitory effect on histamine
release from both rat basophilic leukemia (RBL-2H3) cells
by antigen stimulation and rat peritoneal mast cells stim-
ulated by compound 40/80.11 These findings collectively
indicate that ACT may have anti-allergic effects and there-
fore prompted us to evaluate their therapeutic effect on
patients with atopic dermatitis (AD) in a pilot study.
METHODS
Sample preparations
The ACT from unripe apples were obtained according to
the method reported by Ohnishi-Kameyama et al.12
Subjects
This pilot study was conducted at the Atopy Outpatient
Clinic of Kojima Hospital, one of the affiliated institutions
of Kansai Medical University. Twenty-four patients with
AD, from whom informed consent was obtained, were
enrolled in the study. They were alternatively divided into
one of the two groups, the ACT group (14 patients) and
the control group (10 patients, because four patients
were dropped out). Their ages ranged from 8 to 18 years
(Table 1). They had no other allergic diseases, including
bronchial asthma and allergic rhinitis. The diagnosis of
AD was made on the basis of the morphologic appear-
ance and distribution of skin lesions, the clinical course
and the family history of atopic disease, as described by
Hanifin and Rajka.13
Study design
During the first 2 weeks of the study period (the observa-
tion period), the patients of the both groups were placed
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on the standardized therapy. Briefly, bufexamac (Anderm®,
Takeda Co. Ltd, Osaka, Japan) and half doses of alclomet-
asone dipropionate (Almeta®, Shionogi Co. Ltd, Osaka,
Japan) ointments for topical applications and hydroxyzine
hydrochloride (Atarax P) for antihistamine drug were used in
all patients from the observation period to the end of the
study. There was no difference in the doses of those drugs
between the two groups during the study period. During the
total study period of 10 weeks, none of the subjects
received systemic steroids. During the 8 weeks following the
observation period, the ACT group received ACT supple-
mentation during the subsequent 8 weeks at a dosage of
10 mg/kg divided into two oral doses and the standardized
therapy was continued. In contrast, the control group con-
tinued the standardized therapy following the observation
period. The severity of AD was determined every 2 weeks
during the study period by the scoring system proposed by
Kimata and Igarashi.14 Briefly, grading of skin scores was
0–2 in ascending order of severity with respect to inflamma-
tion, lichenification and cracking, respectively. These signs
were assessed on four areas of the body, that is, face, trunk,
arms, legs, and the maximum possible score was 24.
Scores for itching and sleep disturbance were graded 0–3
in ascending order of severity. The grading of skin scores
was 0–30 (mild, less than 10 points; medium, 11–20
points; severe, more than 21 points).
Peripheral eosinophil counts, serum IgE, glutamic
oxaloacetic transaminase (GOT) and glutamic pyruvic
transaminase (GPT) levels were recorded at the start and
the end of the study in both groups.
Statistical analysis was by the Kruskal–Wallis and
Wilcoxon rank sum tests, with statistical significance set at
P < 0.05. Data are presented as the mean + SD.
RESULTS
Characteristics of the patients are shown in Table 1.
There were no significant differences between the two
groups in sex, age, serum IgE, peripheral eosinophil
counts, grading scores of AD and duration of AD. The
changes in grading scores of AD during the study period
are shown in Fig. 1. Total, inflammation, lichenification
and cracking scores of ACT group decreased after ACT
supplement (Fig. 1a–d). Itching and sleep disturbance
scores of the ACT group more rapidly decreased than in
those of control (Fig. 1e,f ). Peripheral eosinophil counts
of the ACT group significantly decreased during the study
period. Changes of peripheral eosinophil counts before
and after ACT supplementation were as follows: 760 ±
275 versus 525 ± 217 /m L (P < 0.01). In contrast,
there was no statistical difference in peripheral blood
eosinophils of control group during the study period
(784 ± 368 vs 673 + 206 / m L). There was no signifi-
cant decrease in serum IgE, GOT and GPT levels
between the two groups. There was no obvious side-
effect of ACT supplementation.
DISCUSSION
Many researchers have reported that tannins have bio-
logic activities, such as antitumor activity,15–20 antioxidant
activity9,10,21,22 and anti-human immunodeficiency virus
(HIV) activity.23,24 However, the biologic effects of oral
tannins remain obscure, because it is not clear whether
tannins are absorbed in the intestine. Kanda et al. have
described that ACT is a mixture of oligomeric pro-
cyanidins containing the dimer to the pentadecamer 
of epicatechin as a unit.11 Hackett and Griffiths have
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Table 1 Characteristics of the patients with atopic dermatitis
ACT group Control group
No. subjects (male/female) 14 (6/8) 10 (4/6)
Age (years) 13.3 ± 3.8 14.1 ± 2.1
(6–18) (11–17)
Serum IgE (IU/mL) 1944 ± 231 2007 ± 1626
(137–8600) (290–6200)
Peripheral eosinophil counts (/m L) 760 ± 275 784 ± 368
(280–1223) (290–1620)
Grading scores of AD 17.3 ± 3.0 16.4 ± 2.7
(13–24) (13–22)
Duration of AD (years) 8.8 ± 3.9 6.1 ± 1.9
(1–15) (3–10)
ACT, apple condensed tannins; AD, atopic dermatitis.
reported that orally administered catechin is absorbed
and detected in the serum, liver, lung and skin in rats.25
Das has reported that at least 10–20% of the oral cate-
chin is absorbed and finally excreted in the urine and
feces in man.26 In the present study, we showed that
ACT supplement given to the patients at a dosage of 
10 mg/kg per day improved the symptomatic problems
of the patients with AD. These results suggest that ACT is
absorbed through the intestine and may have biologic
activities in vivo.
Kanda et al. have demonstrated that ACT inhibits
the histamine release from RBL2H3 cells during antigen-
specific stimulation by the antigen-IgE complex with
anti-dinitrophenol (DNP) IgE and DNP-bovine serum
albumin (BSA).11 Zhu et al. have reported that poly-
phenols inhibit the binding of specific radioligands to
various receptors.27 In the immediate type allergic reac-
tion cascade, IgE sensitizes basophils and mast cells
that have a specific Fc receptor for IgE on the cell surface.
Therefore, it is of interest to know whether ACT affects the
IgE sensitization stage in the cascade and inhibits hista-
mine release.
It is believed that hyaluronidase plays an important
role in the allergic action because some anti-allergic
drugs inhibit hyaluronidase. It has been reported that
ACT inhibits hyaluronidase as strongly as disodium 
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Fig. 1 Effects of apple condensed tannins (ACT) on the grading scores of total, inflammation, lichenification, cracking, itching and
sleep disturbance of atopic dermatitis (a bar shows the mean ± SD). The ACT group ( ) received the ACT supplement during
8 weeks at a dosage of 10 mg/kg per day. The control group (h) continued the standardized therapy. *P < 0.01, †P < 0.05 
compared with the score at 0 weeks.
cromoglycate, which is one of the strongest inhibitors of
hyaluronidase and is clinically used as an anti-allergic
drug.11 These observations suggest that ACT exhibits anti-
allergic activity, not only as an inhibitor of histamine
release, but also as an inhibitor of the enzyme that
increases cell permeability.
In the present pilot study, we tried to clarify the anti-
allergic effects of ACT on patients with AD. Results
showed that ACT supplementation in patients with AD
decreased grading scores of AD, especially in itching and
sleep disturbance scores. We also observed the changes
in peripheral blood eosinophil counts during the study
period, because it is well known that patients with AD are
frequently associated with blood eosinophilia,28 which
correlates to the activity of this disease. Blood eosinophils 
in patients of the ACT-supplemented group were signifi-
cantly decreased when compared with before the study
(P < 0.05). These results suggest that the decrease in
peripheral eosinophil count and/or improvement in skin
scores in AD patients who received ACT supplementation
may be due to anti-allergic effects described by previous
reports.
In conclusion, the oral administration of ACT showed a
beneficial effect on patients with AD. Apple condensed
tannins are therefore a recommended adjunct to the
therapeutic protocol for patients with AD. Fractionation of
ACT according to the polymerization number is now in
progress. Further studies for the isolation of oligomers are
needed to define the structural feature involved in the
anti-allergic effect.
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